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SUMMARY
Recent evidence suggests that alterations in the self-renewal program of stem/progenitor cells can cause
tumorigenesis. By utilizing genetically engineeredmousemodels of neurofibromatosis type 1 (NF1), we dem-
onstrated that plexiform neurofibroma, the only benign peripheral nerve sheath tumor with potential for
malignant transformation, results from Nf1 deficiency in fetal stem/progenitor cells of peripheral nerves. Sur-
prisingly, this did not cause hyperproliferation or tumorigenesis in early postnatal period. Instead, peripheral
nerve development appeared largely normal in the absence of Nf1 except for abnormal Remak bundles,
the nonmyelinated axon-Schwann cell unit, identified in postnatal mutant nerves. Subsequent degeneration
of abnormal Remak bundles was accompanied by initial expansion of nonmyelinating Schwann cells. We
suggest abnormally differentiated Remak bundles as a cell of origin for plexiform neurofibroma.INTRODUCTION
The hallmark feature of neurofibromatosis type 1 (NF1) is the
development of benign peripheral nerve sheath tumor, termed
neurofibroma (Cichowski and Jacks, 2001; Riccardi, 1992; Zhu
and Parada, 2002). NF1 is a common inherited neurological
disease, affecting 1 in 3500 newborns worldwide. Individuals af-
flicted with NF1 are predisposed to a wide spectrum of derange-
ments, including tumors in the peripheral and central nervous
system (PNS and CNS), myeloid leukemia, hyperpigmentation
defects of the skin, bone abnormalities, and learning disabilities.
The NF1 gene encodes a protein product (neurofibromin) com-
posed of 2818 amino acids, which is highly conserved during
evolution. Neurofibromin is a functional Ras GTPase-activating
protein (RasGAP) that negatively regulates Ras signaling by ac-celerating conversion of activated Ras-GTP to inactive Ras-GDP
(Ballester et al., 1990; Xu et al., 1990).
Plexiform neurofibroma is the only neurofibroma subtype that
has the potential to undergo malignant transformation and prog-
ress to malignant peripheral nerve sheath tumors (MPNSTs).
MPNST is the most common malignancy associated with NF1
and is responsible for the majority of mortality observed in
human NF1 patients (Korf, 1999; Woodruff, 1999). Microscopi-
cally, neurofibromas are heterogeneous proliferations com-
posed of a mixture of cells found in normal peripheral nerves,
including Schwann cells, fibroblasts, perineurial-like fibroblasts,
axons, and mast cells. Recent studies from human tumors
(Rutkowski et al., 2000; Serra et al., 2000; Sheela et al., 1990)
and mouse models (Zhu et al., 2002) have established
the Schwann cell lineage as the true neoplastic element inSIGNIFICANCE
Identification of cancer stem cells raises the possibility that human cancers likely arise from the stem or progenitor cells
possessing self-renewal capabilities. However, the nature of the cell(s) of origin of central and peripheral nervous system
tumors remains largely unknown. The development of plexiform neurofibroma during early childhood raises the possibility
that this tumor arises from the transformation of fetal stem/progenitor cells during nerve development. Our study demon-
strated that early tumor formation is characterized by an expansion of fully differentiated nonmyelinating Schwann cells in
a microenvironment with degeneration of normal nonmyelinated axon/Schwann cell relationships and mast cell infiltration.
These observations suggest potential future therapies for preventing neurofibroma formation by stabilizing axon-Schwann
cell interactions and reducing mast cell infiltration.Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc. 117
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Cellular Basis for Neurofibroma Formationneurofibromas. In a mature peripheral nerve, there are two types
of Schwann cells: myelinating and nonmyelinating Schwann
cells (Jessen and Mirsky, 2005). Myelinating Schwann cells
encircle large-diameter (>1 mm) axons with concentric layers
of cell membrane in a 1:1 relationship to form lipid-rich, multi-
lamellar myelin sheaths. Small-diameter axons are embedded
within and separated by cytoplasmic processes of nonmyelinat-
ing Schwann cells. These Schwann cell/axonal complexes,
termed Remak bundles, may contain up to 30 or 40 axons in
mature nerves (Taveggia et al., 2005). If a fully differentiated
Schwann cell is assumed to be the cell of origin of neurofi-
bromas, it remains to be explained how loss of NF1 function
leads to the transformation of axon-bearing differentiated
Schwann cells into the axon-free Schwann cells that populate
neurofibromas.
Clinical studies indicate that plexiform neurofibromas are
often identified during early childhood (Waggoner et al., 2000).
It has been suggested that these tumors are congenital lesions
that arise from fetal stem or progenitor cells during nerve devel-
opment (Riccardi, 1992). The development of the Schwann cell
lineage is a complex process that includes multiple transition
phases from migrating neural crest cells to glial restricted
progenitor cells (Schwann cell precursors) to two mature cell
types—myelinating and nonmyelinating Schwann cells (see
Figure S1 available with this article online) (Jessen and Mirsky,
2005). Although Schwann cell precursors (SCPs) were originally
identified and widely viewed as glial restricted progenitors that
only give rise to Schwann cells in developing peripheral nerves
(Dong et al., 1999; Jessen et al., 1994), more recent evidence
suggests that at least some of these cells are multipotent and
give rise to both Schwann cells andmyofibroblasts during devel-
opment (Joseph et al., 2004; Morrison et al., 1999). Conse-
quently, these cells were also referred to as neural crest stem
cells (NCSCs) (Morrison et al., 1999). In this study, we refer to
these stem/progenitor cells as SCP/NCSCs, which function as
an intermediate cell type between classic migrating neural crest
cells and lineage-committed Schwann cells during nerve devel-
opment (Jessen and Mirsky, 2005). Since loss of heterozygosity
(LOH) or biallelic inactivation of the NF1 gene is a rate-limiting
step for neurofibroma formation (Cichowski et al., 1999; Serra
et al., 1997, 2000), the question arises whether the key LOH
event must occur in fetal stem/progenitor cells during nerve
development to initiate plexiform neurofibroma formation. In
spite of the importance of NF1 as a model for understanding
tumor suppressor gene function, it remains uncertain which
cell type(s) in the neural crest/Schwann cell lineage during
development and/or in adulthood is the cellular target for NF1
mutation and how loss of NF1 in these cells leads to neurofi-
broma formation.
RESULTS
Targeting an Nf1 Mutation into Fetal Stem/Progenitor
Cells during Nerve Development
We previously showed that neural crest-specific Nf1 mutant
mice (Nf1NC) developed hyperplastic lesions in NC-derived sym-
pathetic ganglia and adrenal medulla and died at birth (Gitler
et al., 2003). To circumvent early lethality of the Nf1NC mice,
we utilized a previously published Cre transgenic strain under
118 Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc.the control of the P0 promoter (P0A-cre) (Giovannini et al.,
2000), which expresses Cre in significantly fewer cells within
the PNS during development. We crossed the P0A-cre trans-
genic mice to a Rosa26-LacZ Reporter strain (R26R-LacZ) that
allows us to examine Cre recombinase activity by expression
of the b-galactosidase (b-gal) gene (Soriano, 1999). P0A-cre-
mediated recombination, revealed by X-gal staining, was first
detected in neural crest and its derived tissues in cranial-facial
regions at embryonic day 9.5 (E9.5) (Figure S2). However, signif-
icant b-gal activity was not detected until E11.5 in the trunk
region (Figures S3Aa–S3Ad). At E12.5, when peripheral nerves
start to innervate both forelimbs and hindlimbs, intense X-gal
stainingwas detected in these peripheral nerves (arrows, Figures
S3Ba–S3Bd). To assess the specificity of P0A-cre-mediated
recombination, we performed X-gal staining on serial transverse
sections prepared from the trunk region of E12.5 P0A-cre+/
R26R-LacZ double transgenic embryos. As shown in Figure 1,
b-gal positive cells are specifically distributed throughout the
PNS including developing peripheral nerves (Figures 1A–1L). In
peripheral nerves, b-gal positive cells are colocalized with three
neural crest/Schwann cell lineage markers: p75NGFR (a marker
that is expressed in both migrating neural crest cells and SCP/
NCSCs) (Figures 1A–1C), GAP43 (Figures 1D–1F), and BLBP
(brain lipid binding protein, also known as BFABP or Fabp7)
(Figures 1G–1I). Both GAP43 and BLBP are expressed in SCP/
NCSCs, but not in migrating neural crest cells (Jessen and Mir-
sky, 2005). It is worth noting that unlike GAP43 and BLBP,
p75NGFR is not neural-specific, as it is expressed in both devel-
oping nerves and adjacent muscle cells (Figures 1B and 1C)
(Wheeler et al., 1998). The nonneural expression of p75NGFR
was further confirmed by double-labeling of p75NGFR with an
axonal marker, Tuj1 (arrows, Figure S4). Furthermore, most of
these b-gal-positive cells in sciatic nerves did not express
S100, a marker for differentiated Schwann cells (Figures 1J–1L)
(Jessen and Mirsky, 2005; Murphy et al., 1996). Of note, periph-
eral nerve development in the thoracic region occurs earlier
than in lumbar region. Consistently, a significant number of
S100-positive cells were observed in peripheral nerves in the
thoracic region (arrows, Figure S3C). At the lumbar region, the
transition from migrating neural crest cells to SCP/NCSCs
occurs between E10 and E11 (Britsch et al., 2001). Because
E11.5 is the earliest time point that we could detect significant
b-gal activity in the trunk, we conclude that the major cell type
in the peripheral nerves in the lumbar region including sciatic
nerves undergoing P0A-cre-mediated recombination is the
SCP/NCSC. To further confirm these results, we performed
double immunofluorescence and attempted to colocalize the
b-gal protein with p75NGFR (Figures 1M–1O), GAP43 (Figures
1P–1R), BLBP (Figures 1S–1U), and Sox10 (Figures 1V–1X) (a
marker that is expressed in both migrating neural crest cells
and SCP/NCSCs) (Britsch et al., 2001). Collectively, these dou-
ble-labeling experiments demonstrated that most, if not all of,
the b-gal positive cells expressed all four markers. However,
only a subset of p75NGFR, GAP43, BLBP, or Sox10 positive cells
expressed b-gal protein. To inactivate Nf1 in SCP/NCSCs during
nerve development, we bred P0A-cre transgenic mice to the
Nf1flox/ mice (Zhu et al., 2001) and subsequently generated
Nf1mutantmice with genotypes ofNf1flox/;P0A-cre+ (hereafter,
Nf1P0AKO).
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tion in SCP/NCSCs
Transverse sections from the lumbar region of
X-gal-stained E12.5 P0A-cre/R26R-LacZ double
transgenic embryos were stained with anti-
p75NGFR (A–C), GAP43 (D–F), BLBP (G–I), and
S100 (J–L) antibodies. The dashed lines (B and
C)mark the p75NGFR and b-gal double-positive de-
veloping peripheral nerves. The expression of
p75NGFR (M–O), GAP43 (P–R), BLBP (S–U), or
Sox10 (V–X) in b-gal positive cells was further
confirmed by double immuofluorescence. Arrow-
heads and arrows in X point to Sox10/b-gal dou-
ble-positive cells and Sox10-positive/b-gal-nega-
tive cells, respectively. Scale bars: (A)–(L), 50 mm;
(M)–(X), 25 mm.
trast to normal (Figure 2E) and hyperplas-
tic (Figure 2D) nerves in which Schwann
cells distribute parallel to nerve fibers,
neurofibroma cells are completely disor-
ganized and randomly oriented in a colla-
gen-rich matrix (Figures 2F–2H). The re-
maining mutant mice without evidenceLoss of Nf1 in SCP/NCSCs Induces Neurofibroma
Formation with High Frequency
TheNf1P0AKOmutantmicewere viable, fertile, and indistinguish-
able from their control littermates. However, in the second year
of life, all the mutant mice developed signs of sickness including
lethargy, ruffled hair, skin lesions, or hindlimb paralysis. Histo-
logical analysis revealed that all of the sick mutant mice (n =
14) exhibited neurofibroma formation throughout the PNS. We
focused our analysis on sciatic nerves, because these nerves
are the only parts of the PNS in which the timing and stages of
Schwann cell development are well established (Jessen and
Mirsky, 2005). As compared to control nerves (Figures 2A and
2E), all mutant sciatic nerves were significantly enlarged (Figures
2B–2D). Histological examinations of sciatic nerves revealed that
10 of 14 (71%) mutant mice developed full-blown plexiform
neurofibromas (NF), which, like human counterparts (Kleihues
and Cavenee, 2000), were composed of increased numbers of
elongated spindle-shape cells and infiltrating mast cells in a
matrix rich in collagen fibers (Figures 2B and 2F and Figures
2C and 2G). All the neurofibromas analyzed in this model
expressed S100 and p75NGFR (Figure S5), which often serve as
diagnostic markers for human neurofibromas. The neurofibroma
tissues were always identified adjacent to preneoplastic lesions
(referred to as hyperplasia, Figures 2B and 2C). The major histo-
pathological distinction between hyperplasia and a fully devel-
oped neurofibroma is that hyperplasia does not disrupt normal
nerve structure in spite of increased cellularity. Figure 2D illus-
trates an example of advanced hyperplasia, characterized by
dramatically increased cellularity with numerous blood vessels
(arrowheads) and infiltrating mast cells (arrows), but with persis-
tence of normally arrayed axons. In contrast, a neurofibroma
identified in adjacent areas was characterized histologically by
complete disruption of nerve structure with only small numbers
of residual myelinated nerve fibers (arrows, Figure 2H). In con-of neurofibroma formation in sciatic
nerves (n = 4, 29%) developed an intermediate lesion that we
referred to as ‘‘hyperplasia with focal neurofibroma’’ (hyperpla-
sia/NF). Histopathologically, hyperplasia/NF is characterized as
an overall hyperplastic lesion with focal areas displaying the dis-
ruption of peripheral nerve architecture characteristics of neuro-
fibroma (Figures 7C, 7G, and 7K). Notably, all of these 4 mutant
mice also developed large cutaneous or subcutaneous neurofi-
bromas (data not shown), raising the question of whether the
presence of these lesions in some way precludes hyperplasia/
NF in sciatic nerves from progressing to full-blown neurofi-
bromas. Together, these observations indicate that Nf1 inacti-
vation in SCP/NCSCs in sciatic nerves induces neurofibroma
formation with high frequency.
To test whether differentiated Schwann cells are susceptible
to neurofibroma formation, we analyzed sciatic nerves of a previ-
ously characterized Nf1 mutant strain (Nf1flox/;Krox20-cre+,
referred to as Nf1Krox20KO) (Zhu et al., 2002). In sciatic nerves,
the Krox20-cre transgene (also known as Egr2-cre) is first ex-
pressed at E15.5 S100+ immature Schwann cells at moderate
levels.Krox20-cre becomes highly expressed duringmyelination
and is maintained in myelinating Schwann cells in adulthood
(Figure S1) (Garratt et al., 2000; Ghislain et al., 2002; Voiculescu
et al., 2000). None of the sciatic nerves analyzed from 16 aged
Nf1Krox20KO mutant mice along with 3 control littermates (12–
16 months old) exhibited any evidence of neurofibroma forma-
tion (Figures 2I–2P). In contrast, all of these mutant mice devel-
oped multiple neurofibromas in cranial nerves and spinal roots
(Zhu et al., 2002) where Krox20-cre is expressed in E10.5 neural
stem/progenitor cells during early nerve development (Figures
S6A–S6C) (Hjerling-Leffler et al., 2005; Maro et al., 2004).
The level of Krox20-cre-mediated Nf1 deletion between sciatic
nerves and spinal roots was not significantly different (Fig-
ure S6D). Furthermore, the level of Cre-mediated recombination
in adult sciatic nerves between P0A- and Krox20-cre transgenic
Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc. 119
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Cellular Basis for Neurofibroma FormationFigure 2. Histological Analysis of Control
and Mutant Sciatic Nerves
Sciatic nerves from control (A and E) and three
Nf1P0AKO mice ([B] and [F], [C] and [G], and [D]
and [H]) were sectioned and stained with hema-
toxylin and eosin (H&E). The dashed lines (B and
C) mark the border of neurofibromas (arrows, [C])
and hyperplasia in mutant nerves. Arrows in (B)
and (D) point to infiltrating mast cells and arrow-
heads (D) point to blood vessels. Sections from
sciatic nerves of control (I and M) and three
Nf1krox20KO ([J] and [N], [K] and [O], and [L] and
[P]) mice were stained with H&E. These mutant
mice only developed varying degrees of hyperpla-
sia in sciatic nerves. Scale bar, 100 mm.
axons (Figures 3H, 3I, and 3L), a signifi-
cant number of which had an abnormal
‘‘dilated’’ morphology in cross sections.
The maximum number of axons per
pocket in the control nerves was 17 as
compared to 41 in the mutant nerves. Inmice was also not significantly different (Figures S6E and S6F).
Therefore, these results suggest that the timing of Nf1 inactiva-
tion, but not the number of Nf1-deficient cells generated by
Krox20- and P0A-cre transgenes in peripheral nerves, is critical
for the discrepancy in tumor penetrance observed in these two
neurofibroma models. Together, these results suggest that in
order to efficiently form neurofibromas, Nf1 must be deleted
from fetal stem/progenitor cells (SCP/NCSCs) in developing pe-
ripheral nerves.
The Role of Nf1 in Schwann Cell Development
The genetic studies described above raise the question of
whether Nf1 deficiency leads to the hyperproliferation of fetal
stem/progenitor cells (SCP/NCSCs) throughout the late gesta-
tion and the early postnatal period, despite the fact that tumors
did not become grossly evident until late adulthood. To test
this, we examined sciatic nerves of the Nf1P0AKO mutant mice
at postnatal day 22 (P22), a time point when Schwann cell devel-
opment is nearly complete. Surprisingly, no significant difference
in cell density and p75NGFR expression was detected between
sciatic nerves of control andmutant mice (Figures 3A–3E). More-
over, ultrastructural analysis obtained with transmission electron
microscopy (TEM) revealed no difference in the number of mye-
linating and nonmyelinating Schwann cells between control and
mutant sciatic nerves (Figure S7A). The number of axons within
the Remak bundles of mutant sciatic nerves was not significantly
altered when compared to the control nerves (Figure 3F, Fig-
ure S7B). These observations indicate thatNf1 does not regulate
the generation or overall differentiation of myelinating or non-
myelinating Schwann cells from fetal stem/progenitor cells in
developing peripheral nerves. However, unlike control Remak
bundles (Figure 3G) in which most of individual axons were seg-
regated into single Schwann cell pockets (Taveggia et al., 2005),
some mutant Remak bundles exhibited a Schwann cell ‘‘pocket
defect’’ that contained aberrantly large numbers of unseparated
120 Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc.addition, some of the abnormal Remak
bundles with poorly segregated and dilated axons underwent
aberrant myelination (Figure 3K), a phenomenon that was never
observed in wild-type nerves (CTR versus Mut, p = 0.004). Mye-
linated Remak bundles with smaller numbers of axons were
found in one Nf1 heterozygous mouse (Figure 3J). Thus, these
data suggest thatNf1 is required for appropriate axonal segrega-
tion and suppression of myelination in at least some nonmyeli-
nating Schwann cells.
Degeneration of Abnormal Remak Bundles
To investigate the possible mechanisms by which abnormal
Remak bundles lead to neurofibroma formation, we analyzed
sciatic nerves of control and Nf1P0AKO mutant mice at older
ages. At 3 months of age (P90), although there was no significant
difference in size between control and mutant sciatic nerves, the
cellular density of mutant sciatic nerves was significantly in-
creased as compared to that of control nerves (Figures S9A
and S9B; Figure 3E). EM analysis indicated that the number of
myelinating Schwann cells in mutant P90 sciatic nerves was
not significantly different from that of controls (Figures 4A–4C;
Figure S7C). Thus, these observations indicate that myelinating
Schwann cells do not contribute to initial cellular expansion in
P90 mutant nerves. In the nonmyelinating Schwann cell lineage,
most of the abnormally differentiated Remak bundles with
unseparated or poorly segregated axons observed in P22 mu-
tant sciatic nerves were no longer detected. The small number
of such abnormal Remak bundles identified at P90 had ‘‘broken’’
Schwann cell pockets in which axons were dissociating from
each other and from their supporting Schwann cells (arrows, Fig-
ures 4E and 4F), which was never observed in control Remak
bundles (Figure 4D). Since these abnormal Remak bundles typi-
cally containedmore than 10 axons (10+), we compared the num-
ber of axons ensheathed by nonmyelinating Schwann cells within
each Remak bundle between control andmutant nerves. Consis-
tent with the degenerating morphology of abnormal Remak
Cancer Cell
Cellular Basis for Neurofibroma Formationbundles, we found that the normal Remak bundles containing
10+ axons in mutant nerves were dramatically reduced as com-
pared to controls (bottom panel, Figure 4O). Loss of the specific
populations of the normal Remak bundles (10+) in P90 mutant
nerves suggests that these cells either died or converted to other
abnormal cells. To test these two possibilities, we first employed
Figure 3. Abnormal Remak Bundles in Nf1 Mutant Sciatic Nerves
Sections of sciatic nerves from P22 control and Nf1P0AKO mutant mice were
stained with H&E (A and B) and anti-p75NGFR antibody (C and D). (E) Quantifi-
cation of the number of cells per surface area (mm2) in P22 and P90 control and
mutant sciatic nerves. For P22 analysis, 8 control and 3 mutant mice were
used, and for P90 analysis, 3 control and 7mutantmicewere used. Cell density
for the P22 and P90 is plotted asmean ± SEM. (F) The numbers of Remak bun-
dles per surface area (1,000 mm2) in control andmutant P22 sciatic nerveswere
categorized into five groups based upon the number of axons that they en-
sheathed. N values represent Remak bundles quantified for each genotype.
Data in (F) represent mean ± SEM from 2 control and 4 mutant nerves. Trans-
mission electron microscopy (TEM) analysis of Remak bundles in sciatic
nerves of P22 control (G and J) and mutant (H, I, and K) mice show abnormal
axonal segregation in the mutant mice. Arrowheads in [G] indicate Schwann
cell cytoplasm between different axons, which isolates each individual axon
into a dedicated Schwann cell pocket in the Remak bundle. Mutant Remak
bundles contain unsegregated axons, which remain directly apposed to
each other (arrowheads, [H], [I], and [K]). (J and K) The number of myelinated
Schwann cells ensheathing multiple axons (arrows) is significantly increased
in mutants compared to controls (p = 0.0036). (L) The percentage distribution
of axons per Schwann cell pocket in control and mutant nerves. N values indi-
cate the number of Schwann cell pockets counted for each genotype (mean ±
SEM). The majority of axons in control nerves were segregated into individual
pockets, while the number of axons properly segregated was dramatically re-
duced in mutant nerves (Chi-square goodness-of-fit test, p < 0.0001). A, my-
elinated axons; a, unmyelinated axons; a*, dilated axons. Scale bars: (A)–(D),
100 mm; (G)–(K), 1 mm.three independent assays to examine whether excess apoptotic
cells were present in mutant nerves. No excess apoptotic cells
were identified by expression of activated Caspase 3 or by a
TUNEL assay in control or mutant sciatic nerves of P22 and
P90 mice (Figures S8A–S8H). Furthermore, by using EM, we ex-
amined the morphology of over 1,500 nonmyelinating Schwann
cells in control and mutant sciatic nerves of P22 and P90 mice.
No cell exhibited classic morphology of apoptotic Schwann cells
such as coarse chromatin, aggregation in the nucleus, vacuola-
tion in the cytoplasm (Figure S8I) (Feldman et al., 1999). These
results indicate that excess apoptosis is not likely to account
for the loss of abnormally differentiated Remak bundles ob-
served in mutant nerves.
Next, to test the possibility whether these abnormal Remak
bundles converted into other cells, we quantified the number
of the different cell types in control and mutant sciatic nerves
of P90 mice by EM (Figure S7C). The cells with Schwann cell
morphology, defined by presence of a continuous basal lamina
and association with axon(s), constitute approximately 98% of
the total cells in the endoneurial space in these EM cross sec-
tions of both control and mutant nerves. We identified three
abnormal Schwann cell populations in mutant nerves that were
rarely seen in control nerves (Figures 4D–4O). Abnormal non-
myelinating Schwann cells (anmSCs) were characterized by an
association of morphologically abnormal axons (e.g., dilated or
naked axons), many of which had myelin-like fragments (Figures
4G–4I). Dissociating Schwann cells (dSCs) were characterized
by presence of free Schwann cell processes (arrowheads, Fig-
ures 4J and 4K), which progressively dissociated from axons
leading to degeneration of unmyelinated axons (arrows, Figures
4K and 4L). Unassociated Schwann cells (uSCs) completely lost
axonal contact in spite of presence of a continuous basal lamina
that sometimes encircled collagen fibers (Figures 4M and 4N).
The uSCs are morphologically identical to the tumor cells ob-
served in both human and mouse neurofibromas (Figure S14)
(Cichowski et al., 1999; Lassmann et al., 1977; Zhu et al.,
2002). Both anmSCs and dSCs share fundamental features
with nonmyelinating Schwann cells: ensheathing small-diameter
axon(s) and possessing a continuous basal lamina (Figures 4G–
4L). However, most of these abnormal Schwann cells, particu-
larly dSCs, contained fewer numbers of axons (<10) compared
to normal nonmyelinating Schwann cells (Figure 4O). Together,
these observations suggest that the Remak bundles with large
numbers of axons (10+), which were specifically lost in mutant
nerves, had broken down into bundles with smaller numbers
of axons that were identified within both normal and abnormal
(anmSCs and dSCs) Remak bundles. Consistent with this,
when we counted and pooled the total axons from all three
populations of nonmyelinating Schwann cells in mutant nerves
(nmSCs, anmSCs, and dSCs), we found that, as compared to
controls, mutant nerves contained significantly fewer Remak
bundles ensheathing more than 20 axons, but had increased
numbers of Remak bundles containing 10 or fewer axons (Fig-
ure S7D). Thus, these results collectively suggest that abnor-
mally differentiated Remak bundles in mutant nerves are unsta-
ble and degenerate into anmSCs and dSCs. The presence of
anmSCs and dSCs leads to approximately 61% increase (p <
0.01) in the number of nonmyelinating Schwann cells in the EM
cross sections of P90 mutant nerves as compared to controls
Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc. 121
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Electron micrographs show cross-sections of P90 control (A and D) and mu-
tant (B, E, and F) sciatic nerves. (C) The number of myelinating (mSC) and non-
myelinating (nmSC) Schwann cells in P90 control and mutant sciatic nerves
was presented by the cell number per surface area (mean ± SEM). a, abnormal
nmSCs; d, dissociating SCs; nm, normal nmSCs. Arrows in (D) point to a typical
Remak bundle in control nerves containing multiple unmyelinated axons (*). (E)
and (F) show two examples of abnormally differentiated Remak bundles with
‘‘broken pockets’’ that have dissociating axons. Arrows in (E) and (F) point to
unsegregated axons (*) dissociating from each other. (G) and (H) show two rep-
resentative anmSCs containing ‘‘naked’’ axons and myelin-like fragments (ar-
rows). M, normal myelin. (I) and (J) show the morphological similarity between
a pair of anmSC and dSC. Arrows in (I) point to ‘‘naked’’ axons in an anmSC
whose degeneration likely generates free Schwann cell processes seen in
a dSC (arrowheads, [J]). (K and L) Two examples of dSCs with free Schwann
cell processes (arrowheads, [K]) and degenerating unmyelinated axons (ar-
rows). (M and N) Two examples of unassociated Schwann cells (uSCs) with
continuous basal lamina and no axon contact. Arrowheads in (M) point to col-
lagen fibers ensheathed by uSCs, which were also shown in Insets (M) with
higher magnification. Arrows in the Insets of (M) and (N) (top) point to continu-
ous basal lamina in uSCs as compared to a fibroblast process (arrows, bottom
inset in [N]). (O) The numbers of Remak bundles per surface area (1,000 mm2)
in control and mutant sciatic nerves were categorized into five groups
based upon the number of axons that they ensheathed. Data in [O] represent
mean ± SEM from 2 control and 3 mutant nerves. Top panel, abnormal non-
myelinating Schwann cells (anmSCs); middle panel, dissociating Schwann
cells (dSCs); bottom panel, normal nonmyelinating Schwann cells (nmSCs).
*p < 0.05, ***p < 0.001. Scale bar, 1 mm.
122 Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc.(Figure 4C and Figure S7C). uSCs represented a minor popula-
tion of cells in P90 mutant nerves. Because some of them
exhibited only parts of Schwann cell-like processes in the EM
images and, hence, are difficult to quantify accurately, we did
not include uSCs in this analysis. Therefore, the 61% increase
of nonmyelinating Schwann cells observed in P90mutant nerves
most likely is a slight underestimation.
Expansion of Nonmyelinating Schwann Cells
To investigate whether the initial expanded nonmyelinating
Schwann cells observed in mutant nerves are neurofibroma cells
in the early stages of tumorigenesis, we first attempted to identify
specific markers for these cells. Under the light microscope,
except for presence of mild hyperplasia, mutant sciatic nerves
were relatively normal compared to controls at P90 (Figures 5A
and 5B; Figures S9A and S9B). Furthermore, the presence of
excess cells in mutant nerves did not alter overall nerve structure
and differentiation of myelinating Schwann cells, revealed by
S100 staining (Figures S9C and S9D). These observations are
consistent with the EM analysis that the myelinating Schwann
cells were not affected in these hyperplastic mutant nerves.
Since Sox10 is primarily expressed in myelinating Schwann cells
of adult nerves (Berger et al., 2006; Peirano et al., 2000), we used
Sox10 immunofluorescence to quantify the number of myelinat-
ing Schwann cells in control and mutant nerves. Sox10-positive
cells (arrowheads) were comparable in control and mutant
nerves, whereas mutant nerves had significantly more Sox10-
negative cells (arrows, Figures 5C and 5D; Figure S10). These
results are consistent with the EM analysis described above (Fig-
ure 4C) that the cells in the nonmyelinating, but not in the myeli-
nating, Schwann cell lineage, are expanded in P90 mutant
nerves. In addition, these observations also suggest that the
initial expanded cellular population in mutant nerves does not
resemble fetal stem or progenitor cells with regard to Sox10
expression. To further confirm these results, we employed three
additional neural crest/Schwann cell lineage markers, BLBP,
GFAP (glial fibrillary acidic protein), and p75NGFR. The expression
of BLBP is downregulated in mature Schwann cells (Kurtz et al.,
1994; Miller et al., 2003). Consistently, no BLBP expression was
found in control or mutant sciatic nerves of P90 mice (data not
shown). GFAP is probably one of the most reliable markers for
nonmyelinating Schwann cells (Jessen and Mirsky, 2005). Ac-
cordingly, we observed a conspicuous increase in GFAP-posi-
tive cells in mutant nerves as compared to controls (Figures 5E
and 5F; Figure S11). Similar to Sox10, p75NGFR is expressed in
both migrating neural crest cells and SCP/NCSCs during early
nerve development. However, in contrast to Sox10, p75NGFR
is only expressed in the nonmyelinating Schwann cell popula-
tions in adult nerves. In conjunction with the ultrastructural
changes noted above, the expression pattern of Sox10 and
BLBP provide compelling evidence that no stem or progenitor
cells persisted into adult Nf1mutant nerves. Hence, the expres-
sion of p75NGFR can be used as a surrogate marker for nonmye-
linating Schwann cells in adult mutant nerves. The increased
number of p75NGFR-expressing cells was identified in mutant
nerves compared to controls. These results were demonstrated
by two independent assays: immuohistochemistry (Figures 5G
and 5H; Figures S9E, S9F, and S12) and flow cytometry (Figures
5I and 5J). Because both GFAP and p75NGFR have diffuse
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tions in P90Mutant Nerves Express Lineage
Markers by Nonmyelinating Schwann Cells
Sections from sciatic nerves of P90 control and
mutant mice were stained with H&E (A and B),
Sox10/DAPI (DAPI stains for cell nuclei) (C and
D), GFAP/DAPI (E and F), and Tuj1/p75/DAPI (G
and H). Arrows and arrowheads in (C) and (D) point
to Sox10-negative and Sox10-positive cells, re-
spectively. The number of GFAP-positive and
p75NGFR-positive cells was conspicuously in-
creased in mutant nerves (arrows, [F] and [H])
compared to controls (arrows, [E] and [G]). Arrow-
heads in (F) and (H) point to a cluster of GFAP-pos-
itive and p75NGFR-positive nuclei in mutant nerves,
which were never seen in controls. Representative
flow-cytometry plots demonstrate approximately
a 2.5-fold increase in frequency of p75NGFR-posi-
tive cells in mutant nerves (21.75%, [J]) compared
to that in control (6.27%, [I]) and a 1.3-fold in-
crease in frequency of BrdU-positive cells in mu-
tant (0.476%, [J]) nerves compared to controls
(0.209%, [I]) nerves. Data in (K) represent mean ±
SEM from two independent experiments using
age-matched control (n = 2) and mutant (n = 4)
mice. *p < 0.05, **p < 0.01. Statistical significance
is indicated by * or **. Sections from sciatic nerves
of BrdU-treated control (L) and mutant (M) mice
were stained with anti-BrdU. The inset in (L) shows a p75NGFR/BrdU double-positive cell in a control nerve. ([N] and [O] and [P] and [Q]) Two representative mutant
nerves showing a cluster of p75NGFR/BrdU double-positive cells (arrows). Scale bar, 50 mm.expression pattern in the cytoplasm that could not always readily
becolocalizedwith thecell nuclei,weemployedflowcytometry to
quantify thenumberofp75NGFR-expressingcells in sciatic nerves.
In two independent experiments, the frequency of p75NGFR-
expressing cells isolated by fluorescence-activated cell sorting
(FACS) was approximately 2.5-fold higher in mutant nerves than
that in controls (Figures 5I–5K), which agreed verywell with the in-
crease in Sox10-negative cells (2.1-fold increase; Figure S10K). It
is worth noting that the increase observed in the Sox10-negative
or p75NGFR-positive cell populationsofmutant nerves ismarkedly
higher than the increased numbers of non-myelinating Schwann
cells obtained fromEManalysis (61%). Thisdiscrepancycould re-
flect the fact that we were using longitudinal sections for quanti-
fying Sox10-positive or -negative cells whereas EM images
were taken from cross-sections of the nerves. Together, these
results demonstrate that the expanded cellular populations in
P90 mutant nerves not only morphologically resemble differenti-
ated nonmyelinating Schwann cells at ultrastructural level (e.g.,
ensheathing small-diameter axons), but also exhibited molecular
characteristics that are similar to nonmyelinating Schwann cells
(BLBP/Sox10/GFAP+/p75+), but not to the fetal stem/progeni-
tor cells (BLBP+/Sox10+/GFAP/p75+).
The Expanded Nonmyelinating Schwann Cells Exhibit
the Characteristics of Early-Stage Neurofibroma Cells
To investigate whether the expanded nonmyelinating Schwann
cells in Nf1 mutant nerves exhibit the characteristics of tumor
cells, we examined proliferation of these cells. In normal P90
nerves, only about 0.2% of the total cells were proliferating, re-
vealed by BrdU staining in the FACS plot (Figure 5I). There was
nearly 1.3-fold increase in the number of BrdU-positive cells inmutant nerves (Figure 5J) as compared to controls (Figure 5I). Al-
though the number of BrdU-positive cells was increased in both
p75NGFR-positive and p75NGFR-negative cellular compartments,
only the p75+/BrdU+ cells were statistically significant more in
mutant nerves than those in control nerves (Figure 5K). To con-
firm these FACS analyses, we performed BrdU-labeling experi-
ments on the tissue sections from P90 control andmutant sciatic
nerves. Consistent with the FACS results, very fewBrdU-positive
cells could be identified in control nerves, which were evenly
distributed throughout the nerve (Figure 5L). In contrast, signifi-
cantly more BrdU-positive cells were identified in mutant nerves
(arrows, Figure 5M; p = 0.02). Many of the mutant BrdU-positive
cells also expressed p75NGFR and distributed in clusters (Figures
5N–5Q), a characteristic of tumor cells that was never observed
in control nerves. Furthermore, a cluster of GFAP or p75NGFR-
positive nuclei could readily be identified in mutant nerves (ar-
rowheads, Figures 5F and 5H), but not in controls (Figures 5E
and 5G).
Both human genetic studies and mouse models have demon-
strated that NF1 deficiency and expansion of NF1/ cells drive
neurofibroma formation. If the expanded p75NGFR-expressing
cells in mutant nerves are early-stage neurofibroma cells, they
should be genetically Nf1 deficient. To mark Nf1-deficient cells
in intact nerve tissues, we introduced the R26R-LacZ allele to
control and mutant mice. Consequently, we could mark Nf1+/
and Nf1/ cells as b-gal-positive cells in control (Nf1flox/+;P0A-
cre+;R26RLacZ) and mutant (Nf1flox/;P0A-cre+;R26RLacZ)
nerves, respectively. As compared to controls (Figure 6A), the
number of b-gal-positive cells in mutant (Figure 6B) sciatic
nerves were significantly increased, indicating expansion of
Nf1/ cellular compartment. In control nerves (Figure 6C),
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Cells in P90 Mutant Nerves Express
p75NGFR and GFAP
The R26R-LacZ allele was introduced to the con-
trol and Nf1P0AKO mutant mice. Sciatic nerves
from P90 mice were sectioned and stained with
X-gal (A and B) and X-gal/anti-p75NGFR antibody
(C and D). Sections from mutant nerves were tri-
ple-labeled by anti-p75NGFR (E and I), anti-b-gal
(F and J), and DAPI (H and L). Overlay images
are shown in (G) and (K). Arrows and an arrowhead
in (I) to (L) point to p75NGFR/b-gal double-positive
cells and a p75NGFR/b-gal+ single positive cell,
respectively. Sections from mutant nerves were
triple-labeled by anti-GFAP (M), anti-b-gal (N)
and DAPI (P). An overlay image is shown in panel
(O). Arrows in (M)–(P) point to GFAP/b-gal double
positive cells and arrowheads in the same panels
show a small number of b-gal positive cells that
do not express GFAP. Scale bars, 50 mm.b-gal-positive cells were found in both p75NGFR-positive (arrows)
and negative (arrowhead) cell compartments, indicating that
P0A-cre was targeted to both nonmyelinating and myelinating
Schwann cell lineages. Most of the b-gal positive cells in mutant
nerves expressed p75NGFR (Figures 6D and 6E–6L), indicating
expansion of the b-gal+/p75NGFR+ cellular population. Further-
more, these b-gal positive cells also expressed GFAP (arrows,
Figures 6M–6P), further confirming that they are in the nonmyeli-
nating Schwann cell lineage. Together, these results indicate
that the expanded nonmyelinating Schwann cells exhibited the
key features of neurofibroma cells: increased proliferation, clus-
tering, and most importantly, Nf1 deficiency. Expansion of the
nonmyelinating Schwann cells was accompanied by degenera-
tion of unmyelinated axons, which was revealed by EM analysis
(Figures 4K and 4L) and focal loss of Tuj1 expression in mutant
nerves (compare Figures S12E and S12M to Figures S12A and
S12I). Axonal degeneration also correlated with an inflammatory
response. At P22, no mast cells were identified in either control
or mutant sciatic nerves. In contrast, mutant nerves recruited
over 2.5-fold more mast cells than did controls at P90, a time
point when initial cellular expansion was observed in mutant
nerves (Figure S13). The degenerative microenvironment and
accompanying mast cell infiltration may provide a favorable
niche for proliferation of early-stage tumor cells.
Progression Stages of Neurofibroma Development
The morphological, molecular and genetic analyses described
above suggest that the expanded p75+/GFAP+/b-gal+ (Nf1 defi-
cient) nonmyelinating Schwann cells observed in P90 Nf1P0AKO
mutant sciatic nerves are tumor cells engaged in the early stages
of neurofibroma development. To determine the role of these
early-stage tumor cells during tumor progression, we analyzed
6 healthy Nf1 mutant mice at 6 to 12 months of age, in which
we identified the preneoplastic lesions in sciatic nerves similar
to those seen in end-stage mutant nerves as described above
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hyperplasia/NF are the precursors for neurofibroma. However,
unlike the hyperplastic lesions observed in sciatic nerves of
younger P90 mutant mice (Figure 5B; Figures S9B and S9D),
similar lesions in aged mutant nerves exhibited focal loss of
myelinated axons, revealed by loss of S100 staining (arrows, Fig-
ure 7B) as compared to age-matched controls (Figure 7A). Sig-
nificantly increased p75NGFR expression also occurred in these
mutant nerves (arrows, Figure 7F) compared to controls (Fig-
ure 7E), indicating further expansion of these p75NGFR-express-
ing cell populations (compare Figures 7F and 7J to Figures 7E
and 7I). In semithin sections, control nerves were tightly packed
with myelinated axons with only a small intervening interstitial
space (Figures 7M and 7Q). Aged hyperplastic mutant nerves,
in contrast, were significantly enlarged by an expanded intersti-
tial compartment (Figures 7N and 7R). The expression pattern of
S100 and p75NGFR revealed that hyperplasia/NF (Figures 7C, 7G,
and 7K) and neurofibromas (Figures 7D, 7H, and 7L) had contin-
uous expansion of the p75NGFR-expressing cells similar to that
observed in hyperplasia, leading to further increased interstitial
cellularity and depletion of myelinated axons (Figures 7O and
7S, 7P and 7T, and Figure S14). The expanded cell population
also expressed GFAP and was Nf1 deficient, revealed by in-
creased numbers of GFAP-positive (Figures 8A–8I) and R26R-
LacZ positive cells (Figure S15) in mutant nerves during tumor
progression. Consistent with loss of myelinated axons at later
stages of neurofibroma development, gradual loss of Sox10-
positive cells was observed in these mutant nerves during tumor
progression (Figures 8J–8O). Furthermore, no BLBP expression
was observed in these aged mutant nerves (data not shown). To-
gether, these results suggest that neurofibroma progression is
drivenby continuous expansion of theNf1-deficient cells withmo-
lecular characteristics of nonmyelinating Schwann cells (BLBP/
Sox10/GFAP+/p75+) similar to the early-stage tumor cells that
were identified in sciatic nerves of younger P90 mutant mice.
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Cell of Origin for Plexiform Neurofibroma
In thisstudy,weemployed twoCre transgenicstrains,P0A-creand
Krox20-cre, which, respectively, target anNf1mutation into stem/
progenitor cells and more differentiated Schwann cells in sciatic
nerves. TheNf1P0AKOmice, but not the age-matchedNf1Krox20KO
mice, developed plexiform neurofibromas in sciatic nerves. These
genetic studies provide compelling evidence that plexiform neuro-
fibromas arise most efficiently as a result ofNf1 deletion from fetal
stem/progenitor cells in developing peripheral nerves.
No stem/progenitor cells (NCSCs) have been identified in
normal adult peripheral nerves (Kruger et al., 2002). Thus, the
possible mechanisms underlying transformation of fetal stem/
progenitor cells are that NF1 deficiency (1) promotes self-
renewal of fetal stem/progenitor cells to form hyperplasia or
tumors during or after nerve development is complete and/or
(2) inhibits differentiation of the fetal stem/progenitor cells that
leads to at least some of these undifferentiated cells persisting
into adult nerves and forming tumors at later stages. Our data
Figure 7. Progression Stages of Neurofibroma Formation
Sciatic nerves from control (A, E, and I) and Nf1P0AKO mutant mice harboring
hyperplasia (B, F, and J), hyperplasia with focal neurofibroma (C, G, and K),
and neurofibroma (D, H, and L) were sectioned and stained with anti-S100,
anti-p75NGFR, and H&E. Arrows in (B), (F) and (J) point to focal loss of S100-
positive myelin sheath that was accompanied by increased numbers of
p75NGFR-expressing cells. The dashed lines in (C, G, and K) mark the border
of hyperplasia and neurofibroma tissues. Arrows in (D) and (L) point to residual
S100-positive myelin sheath in a neurofibroma. Arrowheads in (K) and (L) point
to infiltrating mast cells in neurofibroma tissues. Semithin sections of sciatic
nerves from control (M and Q) and mutant mice harboring hyperplasia (N
and R), hyperplasia with focal NF (O and S), and neurofibroma (P and T)
were stained with toluidine blue. The dashed lines in (O) mark the areas under-
going transition from hyperplasia to neurofibroma, which is characterized by
significant loss of myelinated axons at ultrastructural levels. Arrows in (R),
(S), and (T) point to increased numbers of cells between myelinated axons in
mutant nerves compared to controls. Arrowheads (Q–T) point to infiltrating
mast cells, staining metachromatically in this preparation. Scale bars, 100 mm.
show that Nf1-deficient fetal stem/progenitor cells differentiate
according to a normal time course into Schwann cells. In addi-
tion, EM analysis and expression of neural crest/Schwann cell
lineage markers revealed no evidence of stem/progenitor cells
persisting into adult mutant nerves. By employing a well-estab-
lished neural stem cell assay (Morrison et al., 1999), Joseph
et al. found no evidence for the persistence of NCSCs in Nf1-de-
ficient nerves based upon functional clonal assays for the pres-
ence of self-renewing, multipotent stem cells (Joseph et al.,
2008). Together, these data suggest that it is unlikely that persist-
ing Nf1-deficient fetal stem/progenitor cells serve as a direct cell
of origin for plexiform neurofibroma. Rather, the only subtle
phenotypic abnormality identified in postnatal Nf1P0AKOmutant
nerves is the presence of a subset of the Remak bundles with
a Schwann cell ‘‘pocket defect,’’ which failed to appropriately
segregate ensheathed axons. Abnormal axonal segregation
phenotypes observed inNf1mutant Remak bundles are reminis-
cent of those seen in mice with targeted mutations in the type
III neuregulin-1 (NRG1) (Taveggia et al., 2005) or b-secretase
BACE1 that is normally required for cleaving the type III NRG1
precursor into the functional form (Hu et al., 2006; Willem et al.,
2006), suggesting that NF1 may be an intracellular component
of NRG1/ErbB signaling pathway.
Figure 8. The Number of GFAP-Positive Cells Is Gradually Increased
during Neurofibroma Progression with a Concomitant Decrease in
Sox10-Expressing Cells
Adjacent sections from sciatic nerves of aged control and two Nf1P0AKO mu-
tant mice were stained with GFAP (A, B, and C), DAPI (D, E, and F), GFAP/DAPI
(overlay images, [G], [H], and [I]), and Sox10/DAPI (J, K, and L). (M), (N), and (O)
represent high magnification views of (J), (K), and (L). Scale bars, 50 mm.
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bundles with the ‘‘pocket defect’’ were degenerating in sciatic
nerves of P90Nf1P0AKOmutant mice. Most strikingly, degenera-
tion of the abnormal Remak bundles was accompanied by initial
cellular expansion in Nf1P0AKOmutant nerves. At the ultrastruc-
tural level, the expanded cell populations exhibited an inter-
mediate morphology between fully differentiated nonmyelinating
Schwann cells and neurofibroma cells. Thus, the majority of the
expanded cells were morphologically characterized as anmSCs
or dSCs, both of which displayed the defining features of non-
myelinating Schwann cells (e.g., ensheathing various numbers
of small-diameter axons). When we compared the axon number
within each Remak bundle between control and mutant nerves,
there is a conspicuous shift in axonal distribution from the more
Remak bundles ensheathing >20 axons in control nerves to the
more Remak bundles with <10 axons in mutant nerves. Thus,
themorphological similarities of and the differences in axon num-
ber ensheathed by control and mutant nonmyelinating Schwann
cells suggest a lineage relationship between the degenerating
abnormally differentiated Remak bundles with the ‘‘pocket de-
fect’’ andanmSCs/dSCs/uSCs.Specifically,weproposeamodel
for neurofibroma initiation (Figure S16): degeneration of abnor-
mally differentiated Remak bundles in mutant nerves, which pro-
gressively dissociate from axons and breaks into bundles with
smaller numbers of axons, a sequence which eventually gener-
ates a continuum of abnormal Remak bundles, ranging from
anmSC, dSCs to uSCs. The clinical observation that plexiform
neurofibroma is almost exclusively found in individuals with
NF1 germline mutations (Halliday et al., 1991; Woodruff, 1999)
also supports the notion that NF1 plays a critical function(s)
during early nerve development. Together, our results implicate
the abnormally differentiated Remak bundles as a cell of origin
for early-stage neurofibroma cells.
Early-Stage Tumor Cells versus Tumor-Initiating Cells
Our morphological and molecular analyses demonstrate that
initial hyperplasia observed in P90 Nf1 mutant nerves is not due
to expansion by stem or progenitor cells, but rather by fully differ-
entiated nonmyelinating Schwann cells. To establish a cell or
cells as a cell of origin for a tumor, it is necessary to determine
whether these cells are responsible for initiation and progression
of tumors. The term ‘‘tumor-initiating cells’’ was recently used to
describe a subset of human tumor cells that possess stem cell-
like properties and are capable of regenerating tumors when
transplanted into immunodeficient mice (Al-Hajj et al., 2003;
Singhet al., 2004). The ‘‘tumor-initiating cells’’wereoften referred
to as cancer stem cells. However, these tumor-initiating cells
were isolated fromend-stage established tumors,which typically
have accumulated numerous mutations that support its growth
upon xenotransplantation. Therefore, the tumor-initiating cells or
cancer stem cells probably have little or no resemblance to the
early-stage tumor cells, which harbor fewer mutations and are
responsible for initiating tumor formation in primary tumor sites.
Because the early-stage tumor cells typically are present in
smaller numbers and have limited tumorigenic capacities, we de-
signed several in vivo assays to determine their tumor cell char-
acteristics. Given that no stem or progenitor cells were observed
in adultNf1mutant nerves, wewere able to use p75NGFR as a sur-
rogate for the expanded nonmyelinating Schwann cells. First,
126 Cancer Cell 13, 117–128, February 2008 ª2008 Elsevier Inc.both our immunofluorescence and FACS data demonstrate that
most of the proliferating cells were identified in the p75NGFR-pos-
itive cellular compartment, which were significantly increased in
Nf1 mutant nerves. Second, the proliferating p75NGFR-positive
cells histopathologically exhibited an important characteristic of
tumor cells, namely a tendency to form clusters, a phenomenon
that was never observed in control nerves. Third, most impor-
tantly, many of the p75NGFR-positive cells are genetically Nf1
deficient. Finally, during neurofibroma progression, the continu-
ously expanded cellular populations share the molecular and
genetic characteristics (BLBP/Sox10/GFAP+/p75+/Nf1/)
with those early-stage tumor cells. Taken together, our data sug-
gest that the initially expanded nonmyelinating Schwann cells are
early-stage tumor cells, which are responsible for both the initia-
tion and progression of plexiform neurofibromas.
Clinical Implication
Previous studies showed that overexpression of epidermal
growth factor receptor (EGFR) or dominant negative ErbB4 in-
duced similar hyperplastic lesions to that seen in P90 Nf1P0AKO
mutant nerves (Chen et al., 2003; Ling et al., 2005). However,
these transgenic mice did not develop neurofibromas. There-
fore, there must be some intrinsic increase of tumorigenic poten-
tial in Nf1/ dSCs and uSCs and/or extrinsic field effects of
Nf1+/ microenvironment. Intriguingly, we detected unmyelin-
ated axonal degeneration andmast cell infiltration at the initiation
phase of neurofibroma formation. Joseph et al. transplanted
Nf1/ NCSCs into sciatic nerves of adult Nf1+/ mice and
observed no tumor formation 20 months after injection (Joseph
et al., 2008 [this issue of Cancer Cell]). Therefore, it is tempting
to speculate that such a degenerative and inflammatory micro-
environment could provide a favorable niche for initial prolifera-
tion of Nf1/ cells. Thus, the present study suggests potential
future therapies for prevention and treatment of neurofibroma
by stabilizing axon-Schwann cell interactions and reducing
mast cell infiltration.
EXPERIMENTAL PROCEDURES
Control and Conditional Mutant Mice
The control mice used in this study are a pool of phenotypically indistinguish-
able mice with four genotypes: Nf1flox/+;P0A-cre+, Nf1flox/flox;P0A-cre,
Nf1flox/;P0A-Cre, and Nf1+/. The mutant mice used were of the genotype,
Nf1flox/;P0A-cre (mutants). The P0A-cre transgenic strain was initially gener-
ated on the FVB background (Giovannini et al., 2000). After five generations of
being backcrossed to the 129 Svj background, the P0A-cre transgenic mice
were crossed to the Nf1flox/ mice that were maintained on the 129 Svj back-
ground. Subsequent crosses generated control and mutant mice for analysis.
The Rosa26-LacZ allele was maintained on the mixed 129 Svj and C57Bl6
backgrounds. The mutant mice with or without the Rosa26-LacZ allele
exhibited similar phenotypes. All mice in this study were cared for according
to the guidelines that were approved by the Animal Care and Use Committees
of the University of Michigan at Ann Arbor.
Histological, Molecular, FACS, and Statistical Analyses
Detailed descriptions for these experimental procedures are provided in the
Supplemental Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures and
16 supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/2/117/DC1/.
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